<DOC>
	<DOCNO>NCT02445898</DOCNO>
	<brief_summary>The study evaluate pathophysiological effect single dose Methylprednisolone administer prior total hip-arthroplasty ( THA ) surgery . The investigator examine effect orthostatic intolerance , orthostatic hypotension heart rate variability ( HRV ) evaluate efficacy Methylprednisolone regard blood pressure regulation autonomic response THA . Half participant receive intravenous Solu-Medrol 125 mg , half receive placebo . The investigator hypothesize group receive Methylprednisolone le orthostatic intolerant , experience less orthostatic hypotension improve autonomic response compare placebo-group , early THA .</brief_summary>
	<brief_title>Effect Methylprednisolone Orthostatic Intolerance Heart Rate Variability Hip-arthroplasty Patients</brief_title>
	<detailed_description>The anti-inflammatory effect glucocorticoid well know . The beneficial effect postoperative pain , postoperative nausea vomit well-documented . Hip-arthroplasty surgery inflammatory stress response general affect potential recovery . Early postoperative orthostatic intolerance common patient undergoing THA incidence 40 % . The mechanism think relate impaired autonomic regulation cause surgery-induced inflammation . The effect glucocorticoids orthostatic intolerance , orthostatic hypotension HRV hip-arthroplasty surgery unknown call investigation . The study consider exploratory . The primary analysis primary outcome measure comparison incidence orthostatic intolerance baseline 6 hour postoperatively two group . For calculation sample size difference incidence group ( 40 % versus 10 % ) baseline ( surgery ) 6 hour THA-surgery , risk type I errors 5 % risk type II errors 20 % ( 80 % power ) use . The primary analysis carry included patient ( intention-to-treat ) baseline value covariate . Secondary exploratory per-protocol analysis might perform . Missing outcome analyse use multiple imputation due expect strong time trend . The secondary outcome measure ; Non-invasive blood pressure , systemic vascular resistance , cardiac output , HRV , plasma-hemoglobin , C-reactive protein . For detail please also view European Clinical Trials Database ( EudraCT ) registration : EudraCT nr . : 2015-000102-19</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Joint Diseases</mesh_term>
	<mesh_term>Orthostatic Intolerance</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Osteoarthrosis Undergoing total unilateral hiparthroplasty surgery Speak understand Danish Have give inform content Revision bilateral hiparthroplasty surgery General anaesthesia Allergy intolerance towards Methylprednisolone Local systemic infection Permanent systemic treatment steroid within 30 day peroperatively Insulindependent diabetes Atrial fibrillation Neurological disease incl . Parkinsons Daily use hypnotic sedative Alcohol abuse &gt; 35 unit per week Active treatment ulcer within 3 month preoperatively Cancer disease Autoimmune disease incl . rheumatoid arthritis Pregnant breast feed woman Menopause &lt; 1 year</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Glucocorticoid</keyword>
	<keyword>Orthostatic Intolerance</keyword>
	<keyword>Heart Rate Variability</keyword>
	<keyword>Hip arthroplasty , total</keyword>
</DOC>